Cell-based high-content screening (HCS) assays have become an increasingly attractive alternative to traditional in vitro and in vivo testing in pharmaceutical drug development and toxicological safety assessment.
Manufacturers have developed super-corrected optics that allow co-localization studies with much more accuracy than before
« Phenotypic Drug Discovery with High Content Screening » by Permin Elmer
I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.
Poster – High Content Screening of automated wound healing and cytotoxicity assays in 2D and 3D culture
To find anti-cancer drugs, different cellular modifications can be looked at: cell death effect on proliferating cells either in 2D culture or on spheroids (3D culture), anti-mitotic, anti-migration/invasion, anti-angiogenesis effects… Different assays can be performed to follow these different effects. High content screening is a multi-parametric technology allowing searching for poly-effects drugs.
The data analysis and statistics, especially the Z-score that everybody knows, need to be reviewed. Guyon et al boast Φ-score.
In this article, authors emphasize the importance of standardisation in the development of HCS.
It was really interesting to be present at the AFSSI’s “universités d’été”. About 160 business heads of CRO (contract research organisation) in biotechnology area were present. We were also lucky to present our business during the elevator pitch, 5 min to convince, during the 2nd day.
Identification of potential therapeutic target by phenotypic screening for proteinuric kidney diseases
By phenotypic screening, these authors have identified small molecules, that protected podocytes against injury in vitro. This findings identify pyrintegrin as a potential therapeutic candidate and show the use of podocyte-based screening assays for identifying novel therapeutics for proteinuric kidney diseases.
We are really pleased to announce that we have received the award of innovative poster for our Parkinson model and first results in 3D culture.
Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters, one on co-culture model of Parkinson and first results in 3D dimension, and the other one, on genotoxicity and steatosis assay on HepG2 cells.
First assays were performed these two last months on Parkinson disease cell model and we have obtained our first results on neuronal cell line culture and on co-culture of neuronal and macrophagic cells. A nice dose neurotoxicity effect was obtained with rotenone as Parkinson inducer. With these first results, we can Read more…
We are really pleased to work with Perkin Elmer group. We have now our own Columbus server installed in our office for images visualisation and analysis.
Lattice light-sheet microscopy: spatiotemporal resolution high enough to follow fast, nanoscale dynamic processes
This new microscopy technology is a promising tool for in vivo 3D imaging of fast dynamic processes in cells and embryos. Lattice light-sheet microscopy allows fast 3D superresolution, with lower photobleaching and phototoxicity.
More and more articles show the advantages of #3d culture compared to 2D in #oncology field. This article describe how to do high throughput using 3D culture by rapid size profiling analysis over time on tumor spheroids. “Tumor size is the most frequently used in vivo endpoint when assessing antitumor efficacy in Read more…
#hcs produce a lot of #data (pictures, meta-data, results, etc.) and it is not always easy to integrate and #analyse them. In this webinar, James Adams (Senior Regional Marketing Specialist for PerkinElmer) will focus on #spotfire capabilities to integrate data from multiple systems. The ultimate goal of “#big Data” is to Read more…
The Vision Summit interviewed Dr Urban Liebel, co-founder of Acquifer based in Karlsruhe Germany at this year’s NIWeek, on the perspective of development of #hcs machine in the future. This interview tooked place in Austin, Texas at the beginning of August. The development of #next generation HCS machines is possible Read more…
Dr. Kim remarked, “Our research is significant in that we presented a candidate material for a new drug for #diabetes without side effects.” He added, “We will try hard to develop a new drug for type 2 diabetes through a follow-up study using automated equipment for high-content screening recently built Read more…
#hcs by multiplexing assays on #3d cell culture have many advantages to find more efficient new drugs for #cancer treatment. Progress in the IT part, on softwares, on the uses on big data and in the machine on speed and sensitivity allow to do multiplexing assays in HCS . This article Read more…